Abstract
erebral arteriovenous malformations (AVMs) may serve as a considerable source of neurological morbidity as C a result of hemorrhage, seizures, and/or focal neurologic deficits. Hemorrhage remains the most common modality of AVM presentation, occurring in approximately 50% of cases (2, 5, 19). Annual AVM hemorrhage rates generally range from 2% to 4%; however, they are largely influenced by a previous history of hemorrhage and AVM angioarchitecture, particularly drainage pattern, location, and associated aneurysms (2, 5, 19). Protection from hemorrhage remains the primary presumed benefit of AVM treatment, whereas the improvement of seizures still remains a matter of debate (10).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
